![]() NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. ![]() PAs may claim a maximum of 0.25 Category 1 credit for completing this activity. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Paradigm Medical Communications, LLC designates this enduring material for a maximum of 0. Paradigm Medical Communications, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.Ĭredit Designation Physician Credit Designation Statement Recognize differences between the MOAs of conventional anti-VEGF agents versus novel therapies that are approved for the treatment of nAMD and DME.Upon completion of this activity, participants should be able to: Expert faculty commentary, interspersed throughout, elucidates complex topics, and highlights key points. Promising investigational agents that work via novel pathways are also included. This interactive infographic activity allows you to explore, at your own pace and according to your own interests, the mechanisms of action (MOAs) behind dual pathway inhibition with faricimab that help explain its enhanced durability and superior effects on disease activity compared with anti-VEGF therapy. This activity is supported by an educational grant from grant from Genentech, a member of the Roche Group.įor the first time in nearly 2 decades, a novel therapy has been approved for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) that works beyond the traditional vascular endothelial growth factor (VEGF) pathway. ![]() This activity is provided by Paradigm Medical Communications, LLC. It may also benefit other clinicians interested in the management of neovascular retinal diseases. This activity has been designed to address the educational needs of retina specialists and comprehensive ophthalmologists. Chair and UIC Distinguished Professor of Ophthalmologyĭirector, The Retina Service of Wills Eye Hospital MedImmune has been signing a number of research agreements of late, as it looks to build its pipeline of products, and entered a five-year collaboration with Ethris looking into respiratory diseases in August 2017.Įarlier this year it entered a partnership with Compugen for multiple bi- and multi-specific antibodies, though the particular therapeutic area was not revealed.Marion H. MedImmune had not responded to a request for further information on the exact condition that will be targeted or on the financial details of the deal at the time of publishing. Our progress in customised AAV vectors enables us to unlock the potential of gene therapy and, with MedImmune’s expertise in protein engineering, we will continue to push boundaries in proprietary gene delivery to tissues and cells.” In a joint statement, David Kirn, CEO and co-founder of 4DMT, said: “This exciting collaboration may open the door to significant advancements in treatment for respiratory patients. This would allow any potential therapy to bring a ‘blueprint’ for the cell to produce a protein, which could potentially interrupt or alleviate symptoms of chronic lung disease.Īs part of the partnership, 4DMT will work on discovery, engineering and optimising the development process, while MedImmune will work on the clinic development of any therapeutic candidate discovered. AAV vectors are designed to transport genes into both dividing and nondividing cells without introducing genetic material into the host genome. The target for the gene therapy will be chronic lung disease. MedImmune, AstraZeneca’s research and development arm, has opted to work with California-based 4D Molecular therapeutics (4DMT) on its adeno-associated virus (AAV) gene therapy vector discovery and engineering program.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |